Pharma

Your Article Summary

See Latest Articles

Randomized phase 2 study of imc-a12 for her2-expressing advanced breast cancer commences patient enrollment
ImClone Sytems, 11/20/08

ImClone Systems Incorporated, a global leader in the development and commercialization of novel antibodies to treat cancer, announced that its disease-directed randomized Phase 2 clinical trial of IMC-A12 in patients with previously treated HER2-expressing locally advanced or metastatic breast cancer has commenced patient enrollment. IMC-A12 is ImClone's fully human, IgG1 anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody.

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

Greater chances of cure for patients with HER2-positive early breast cancer when treated with one year of Herceptin
Roche, 12/14/09

Avastin plus commonly used chemotherapies improves time without the disease getting worse in women with previously treated advanced breast cancer
Roche, 12/14/09

ImmunoGen, Inc. Announces Positive Trastuzumab-DM1 Clinical Data Reported at the San Antonio Breast Cancer Symposium
ImmunoGen, Inc., 12/14/09

 See all of Research & Development